Abstract 1826P
Background
The global incidence of breast cancer is increasing, highlighting the need for attention not only to treatment but also to long-term survivorship issues. Osteoporosis, an age-related bone disorder, presents a significant concern for patients with breast cancer due to its potential impact on morbidity and mortality. This Korean nationwide cohort study aimed to investigate the occurrence and risk factors of osteoporosis among patients with breast cancer, with a specific focus on gender disparities.
Methods
Using data from the Korean National Health Insurance claim database, we identified individuals diagnosed with ductal carcinoma in situ or breast cancer as their primary diagnosis between 2009 and 2015. Patients diagnosed with osteoporosis were determined based on ICD-10 codes (International Classification of Disease) and medication prescriptions. Propensity score matching was performed to minimize confounding variables.
Results
Among 299 male and 80362 female breast cancer patients, a higher prevalence of osteoporosis was observed in females (n=13423(16.7%) vs n=15(5.0%)). Endocrine therapy was associated with an increased risk of osteoporosis, particularly among females (HR 6.37, 95%CI, 3.74-10.89, p<0.001). Age, steroid medication use, and comorbidity burden were also identified as significant risk factors for osteoporosis. Adjusting other variables, females diagnosed with osteoporosis had a higher incidence of only hip or vertebral fractures compared to males (HR 3.96, 95%CI, 1.24-12.64, p=0.020). While overall fracture incidence was higher in males before matching, gender differences were not significant after propensity score matching.
Conclusions
In conclusion, our study highlights the importance of proactive screening and management of osteoporosis in breast cancer patients, with a focus on gender-specific risk factors. These findings emphasize the necessity of comprehensive bone health assessment and preventive measures to improve long-term outcomes and quality of life for breast cancer survivors. Further research is warranted to elucidate the underlying mechanisms of gender differences in osteoporosis risk and evaluate the effectiveness of targeted interventions in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1864P - Study on the real-life use of G-CSF in patients with lung cancer: Secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG
Presenter: Didier Debieuvre
Session: Poster session 12
1865P - DEFENDOR special: Real-world use of pegylated granulocyte-colony stimulating factor in patients with gastrointestinal cancers
Presenter: Alexey Tryakin
Session: Poster session 12
1866P - Metabolic and quality of life changes with the use of dexamethasone pre-paclitaxel in patients with breast cancer
Presenter: VANESSA SCONTRE
Session: Poster session 12
1867P - Efficacy of lower dose of dexamethasone premedication in patient receiving docetaxel-based chemotherapy in preventing hypersensitivity reaction: A randomized controlled trial
Presenter: Sitthichai Chanmaniloet
Session: Poster session 12
1868P - Development and validation of a clinical prediction model for paclitaxel hypersensitivity reaction: Pac-HSR score
Presenter: Radasar Sukphinetkul
Session: Poster session 12
1869P - Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study
Presenter: Anton Snegovoy
Session: Poster session 12
1870P - Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy
Presenter: Giovanna Giannecchini
Session: Poster session 12
1871P - Temperature-controlled hand-foot cooling combined with compression prevents chemotherapy-induced polyneuropathy (CIPN): A single center, prospective, real-world data collection
Presenter: Athina Kostara
Session: Poster session 12
1872P - Evaluation of PROMISE, grim, and cti scores for predicting 90-day mortality in hospitalized cancer patients: A retrospective analysis at a single center
Presenter: Galip Can Uyar
Session: Poster session 12
1873P - Thalidomide for the treatment of chemotherapy-induced night sweats in patients with pancreatic cancer
Presenter: Nan Lu
Session: Poster session 12